Synergism in hyperhomocysteinemia and diabetes: Role of PPAR gamma and tempol

Cardiovascular Diabetology

Volumn 9, Issue , 2010, Pages

  Mishra, Paras K ^a   Tyagi, Neetu ^a   Sen, Utpal ^a   Joshua, Irving G ^a   Tyagi, Suresh C ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; CIGLITAZONE; CYSTATHIONINE BETA SYNTHASE; GELATINASE B; GLUCOSE; HOMOCYSTEINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; TEMPOL; THIOREDOXIN; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TISSUE INHIBITOR OF METALLOPROTEINASE 4; 2,4 THIAZOLIDINEDIONE DERIVATIVE; AMINE OXIDE; ANTIDIABETIC AGENT; ANTIOXIDANT; GELATINASE A; NOX4 PROTEIN, MOUSE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE-4;

AMINO ACID BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HEART VENTRICLE REMODELING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPERGLYCEMIA; HYPERHOMOCYSTEINEMIA; M MODE ECHOCARDIOGRAPHY; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; CARDIOMYOPATHY; DRUG EFFECT; DRUG POTENTIATION; GENETICS; INSULIN DEPENDENT DIABETES MELLITUS; METABOLISM; OXIDATIVE STRESS; PHYSIOLOGY; SPIN LABELING;

ANIMALS; ANTIOXIDANTS; CARDIOMYOPATHIES; CYCLIC N-OXIDES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; DRUG SYNERGISM; HYPERGLYCEMIA; HYPERHOMOCYSTEINEMIA; HYPOGLYCEMIC AGENTS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; NADPH OXIDASE; OXIDATIVE STRESS; PPAR GAMMA; SPIN LABELS; THIAZOLIDINEDIONES; TISSUE INHIBITOR OF METALLOPROTEINASE-3; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 77956467451     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-9-49     Document Type: Article

References (68)

1. Ciaccio M, Bellia C. Hyperhomocysteinemia and cardiovascular risk: effect of vitamin supplementation in risk reduction. Curr Clin Pharmacol 2010, 5:30-36. 10.2174/157488410790410551, 20236081.
2. Mendez-Gonzalez J, Rodriguez-Millan E, Julve J, Blanco-Vaca F. [Vitamin treatments that lower homocysteine concentration: can they decrease cerebrovascular disease in primary prevention?]. Rev Neurol 2010, 50:235-244.
3. Sen U, Tyagi SC. Homocysteine and Hypertension in Diabetes: Does PPARgamma Have a Regulatory Role?. PPAR Res 2010, 2010:806538. 2895301, 20613990.
4. Audelin MC, Genest J. Homocysteine and cardiovascular disease in diabetes mellitus. Atherosclerosis 2001, 159:497-511. 10.1016/S0021-9150(01)00531-7, 11730832.
5. Dinavahi R, Falkner B. Relationship of homocysteine with cardiovascular disease and blood pressure. J Clin Hypertens (Greenwich) 2004, 6:494-498. 10.1111/j.1524-6175.2004.03643.x, 15365276.
6. Dominguez LJ, Galioto A, Pineo A, Ferlisi A, Ciaccio M, Putignano E, et al. Age, homocysteine, and oxidative stress: relation to hypertension and type 2 diabetes mellitus. J Am Coll Nutr 2010, 29:1-6.
7. Hoogeveen EK, Kostense PJ, Beks PJ, Mackaay AJ, Jakobs C, Bouter LM, et al. Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus: a population-based study. Arterioscler Thromb Vasc Biol 1998, 18:133-138.
8. Hoogeveen EK, Kostense PJ, Jakobs C, Dekker JM, Nijpels G, Heine RJ, et al. Hyperhomocysteinemia increases risk of death, especially in type 2 diabetes: 5-year follow-up of the Hoorn Study. Circulation 2000, 101:1506-1511.
9. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002, 325:1202. 10.1136/bmj.325.7374.1202, 135491, 12446535.
10. Pavia C, Ferrer I, Valls C, Artuch R, Colome C, Vilaseca MA. Total homocysteine in patients with type 1 diabetes. Diabetes Care 2000, 23:84-87. 10.2337/diacare.23.1.84, 10857974.
11. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002, 288:2015-2022. 10.1001/jama.288.16.2015, 12387654.
12. Carroll JF, Tyagi SC. Extracellular matrix remodeling in the heart of the homocysteinemic obese rabbit. Am J Hypertens 2005, 18:692-698. 10.1016/j.amjhyper.2004.11.035, 15882553.
13. Singh AP, Singh M, Balakumar P. Effect of mast cell stabilizers in hyperhomocysteinemia-induced cardiac hypertrophy in rats. J Cardiovasc Pharmacol 2008, 51:596-604. 10.1097/FJC.0b013e31817ae60f, 18520950.
14. Nosaka S, Murata K, Kobayashi M, Cheng ZB, Maruyama J. Inhibition of baroreflex vagal bradycardia by activation of the rostral ventrolateral medulla in rats. Am J Physiol Heart Circ Physiol 2000, 279:H1239-H1247.
15. Wang Y, Jones JF, Jeggo RD, de Burgh DM, Jordan D, Ramage AG. Effect of pulmonary C-fibre afferent stimulation on cardiac vagal neurones in the nucleus ambiguus in anaesthetized cats. J Physiol 2000, 526(Pt 1):157-165. 10.1111/j.1469-7793.2000.t01-1-00157.x, 2269989, 10878108.
16. Koz ST, Gouwy NT, Demir N, Nedzvetsky VS, Etem E, Baydas G. Effects of maternal hyperhomocysteinemia induced by methionine intake on oxidative stress and apoptosis in pup rat brain. Int J Dev Neurosci 2010, 28:325-329. 10.1016/j.ijdevneu.2010.02.006, 20188811.
17. Sibrian-Vazquez M, Escobedo JO, Lim S, Samoei GK, Strongin RM. Homocystamides promote free-radical and oxidative damage to proteins. Proc Natl Acad Sci USA 2010, 107:551-554. 10.1073/pnas.0909737107, 2818928, 20080717.
18. Solini A, Santini E, Nannipieri M, Ferrannini E. High glucose and homocysteine synergistically affect the metalloproteinases-tissue inhibitors of metalloproteinases pattern, but not TGFB expression, in human fibroblasts. Diabetologia 2006, 49:2499-2506. 10.1007/s00125-006-0377-2, 16896935.
19. Solini A, Santini E, Ferrannini E. Effect of short-term folic acid supplementation on insulin sensitivity and inflammatory markers in overweight subjects. Int J Obes (Lond) 2006, 30:1197-1202. 10.1038/sj.ijo.0803265, 16491109.
20. Shastry S, Tyagi SC. Homocysteine induces metalloproteinase and shedding of beta-1 integrin in microvessel endothelial cells. J Cell Biochem 2004, 93:207-213. 10.1002/jcb.20137, 15352177.
21. Rodriguez WE, Sen U, Tyagi N, Kumar M, Carneal G, Aggrawal D, et al. PPAR gamma agonist normalizes glomerular filtration rate, tissue levels of homocysteine, and attenuates endothelial-myocyte uncoupling in alloxan induced diabetic mice. Int J Biol Sci 2008, 4:236-244. 2500152, 18690293.
22. Tyagi SC, Hoit BD. Metalloproteinase in myocardial adaptation and maladaptation. J Cardiovasc Pharmacol Ther 2002, 7:241-246. 10.1177/107424840200700407, 12490970.
23. Fallon UB, Elwood P, Ben-Shlomo Y, Ubbink JB, Greenwood R, Smith GD. Homocysteine and ischaemic stroke in men: the Caerphilly study. J Epidemiol Community Health 2001, 55:91-96. 10.1136/jech.55.2.91, 1731833, 11154247.
24. Fonseca VA, Fink LM, Kern PA. Insulin sensitivity and plasma homocysteine concentrations in non-diabetic obese and normal weight subjects. Atherosclerosis 2003, 167:105-109. 10.1016/S0021-9150(02)00386-6, 12618274.
25. Basu R, Oudit GY, Wang X, Zhang L, Ussher JR, Lopaschuk GD, et al. Type 1 diabetic cardiomyopathy in the Akita (Ins2WT/C96Y) mouse model is characterized by lipotoxicity and diastolic dysfunction with preserved systolic function. Am J Physiol Heart Circ Physiol 2009, 297:H2096-H2108. 10.1152/ajpheart.00452.2009, 19801494.
26. Ishii I, Akahoshi N, Yamada H, Nakano S, Izumi T, Suematsu M. Cystathionine {gamma}-lyase-deficient mice require dietary cysteine to protect against acute lethal myopathy and oxidative injury. J Biol Chem 2010, 20;285(34):26358-68. Epub 2010 Jun 21.
27. Sen U, Munjal C, Qipshidze N, Abe O, Gargoum R, Tyagi SC. Hydrogen sulfide regulates homocysteine-mediated glomerulosclerosis. Am J Nephrol 2010, 31:442-455. 10.1159/000296717, 20395677.
28. Tyagi N, Mishra PK, Tyagi SC. Homocysteine, hydrogen sulfide (H2S) and NMDA-receptor in heart failure. Indian J Biochem Biophys 2009, 46:441-446.
29. Tyagi N, Givvimani S, Qipshidze N, Kundu S, Kapoor S, Vacek JC, et al. Hydrogen sulfide mitigates matrix metalloproteinase-9 activity and neurovascular permeability in hyperhomocysteinemic mice. Neurochem Int 2010, 56:301-307. 10.1016/j.neuint.2009.11.002, 19913585.
30. Tenenbaum A, Fisman EZ, Motro M. Metabolic syndrome and type 2 diabetes mellitus: focus on peroxisome proliferator activated receptors (PPAR). Cardiovasc Diabetol 2003, 2:4. 10.1186/1475-2840-2-4, 153546, 12834541.
31. Folmes CD, Clanachan AS, Lopaschuk GD. Fatty acid oxidation inhibitors in the management of chronic complications of atherosclerosis. Curr Atheroscler Rep 2005, 7:63-70. 10.1007/s11883-005-0077-2, 15683605.
32. Nolte RT, Wisely GB, Westin S, Cobb JE, Lambert MH, Kurokawa R, et al. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature 1998, 395:137-143. 10.1038/25931, 9744270.
33. Itoh H, Doi K, Tanaka T, Fukunaga Y, Hosoda K, Inoue G, et al. Hypertension and insulin resistance: role of peroxisome proliferator-activated receptor gamma. Clin Exp Pharmacol Physiol 1999, 26:558-560. 10.1046/j.1440-1681.1999.03082.x, 10405788.
34. Lebovitz HE, Banerji MA. Insulin resistance and its treatment by thiazolidinediones. Recent Prog Horm Res 2001, 56:265-294. 10.1210/rp.56.1.265, 11237217.
35. Marx N, Sukhova G, Murphy C, Libby P, Plutzky J. Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma(PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro. Am J Pathol 1998, 153:17-23. 1852950, 9665460.
36. Bissonnette R, Treacy E, Rozen R, Boucher B, Cohn JS, Genest J. Fenofibrate raises plasma homocysteine levels in the fasted and fed states. Atherosclerosis 2001, 155:455-462. 10.1016/S0021-9150(00)00584-0, 11254917.
37. Blane GF. Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives. Am J Med 1987, 83:26-36. 10.1016/0002-9343(87)90868-0, 3318450.
38. Dierkes J, Westphal S, Luley C. Serum homocysteine increases after therapy with fenofibrate or bezafibrate. Lancet 1999, 354:219-220. 10.1016/S0140-6736(99)02153-4, 10421307.
39. Brude IR, Finstad HS, Seljeflot I, Drevon CA, Solvoll K, Sandstad B, et al. Plasma homocysteine concentration related to diet, endothelial function and mononuclear cell gene expression among male hyperlipidaemic smokers. Eur J Clin Invest 1999, 29:100-108. 10.1046/j.1365-2362.1999.00419.x, 10092996.
40. Barger PM, Brandt JM, Leone TC, Weinheimer CJ, Kelly DP. Deactivation of peroxisome proliferator-activated receptor-alpha during cardiac hypertrophic growth. J Clin Invest 2000, 105:1723-1730. 10.1172/JCI9056, 378509, 10862787.
41. Hunt MJ, Tyagi SC. Peroxisome proliferators compete and ameliorate Hcy-mediated endocardial endothelial cell activation. Am J Physiol Cell Physiol 2002, 283:C1073-C1079.
42. Yamamoto K, Ohki R, Lee RT, Ikeda U, Shimada K. Peroxisome proliferator-activated receptor gamma activators inhibit cardiac hypertrophy in cardiac myocytes. Circulation 2001, 104:1670-1675. 10.1161/hc4001.097186, 11581147.
43. Jagadeesha DK, Lindley TE, Deleon J, Sharma RV, Miller F, Bhalla RC. Tempol therapy attenuates medial smooth muscle cell apoptosis and neointima formation after balloon catheter injury in carotid artery of diabetic rats. Am J Physiol Heart Circ Physiol 2005, 289:H1047-H1053. 10.1152/ajpheart.01071.2004, 15833798.
44. Viswanad B, Srinivasan K, Kaul CL, Ramarao P. Effect of tempol on altered angiotensin II and acetylcholine-mediated vascular responses in thoracic aorta isolated from rats with insulin resistance. Pharmacol Res 2006, 53:209-215. 10.1016/j.phrs.2005.11.002, 16412660.
45. Johansen JS, Harris AK, Rychly DJ, Ergul A. Oxidative stress and the use of antioxidants in diabetes: linking basic science to clinical practice. Cardiovasc Diabetol 2005, 4:5. 10.1186/1475-2840-4-5, 1131912, 15862133.
46. Watanabe M, Osada J, Aratani Y, Kluckman K, Reddick R, Malinow MR, et al. Mice deficient in cystathionine beta-synthase: animal models for mild and severe homocyst(e)inemia. Proc Natl Acad Sci USA 1995, 92:1585-1589. 10.1073/pnas.92.5.1585, 42564, 7878023.
47. Sivarajah A, McDonald MC, Thiemermann C. The cardioprotective effects of preconditioning with endotoxin, but not ischemia, are abolished by a peroxisome proliferator-activated receptor-gamma antagonist. J Pharmacol Exp Ther 2005, 313:896-901. 10.1124/jpet.104.080598, 15734901.
48. Evans M, Anderson RA, Graham J, Ellis GR, Morris K, Davies S, et al. Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus. Circulation 2000, 101:1773-1779.
49. Scatena R, Bottoni P, Giardina B. Mitochondria, PPARs, and Cancer: Is Receptor-Independent Action of PPAR Agonists a Key?. PPAR Res 2008, 2008:256251. 2464819, 18645611.
50. Guo L, Zhang L, Sun Y, Muskhelishvili L, Blann E, Dial S, et al. Differences in hepatotoxicity and gene expression profiles by anti-diabetic PPAR gamma agonists on rat primary hepatocytes and human HepG2 cells. Mol Divers 2006, 10:349-360. 10.1007/s11030-006-9038-0, 17031537.
51. Sen U, Tyagi N, Kumar M, Moshal KS, Rodriguez WE, Tyagi SC. Cystathionine-beta-synthase gene transfer and 3-deazaadenosine ameliorate inflammatory response in endothelial cells. Am J Physiol Cell Physiol 2007, 293:C1779-C1787. 10.1152/ajpcell.00207.2007, 17855772.
52. Tyagi SC, Smiley LM, Mujumdar VS. Homocyst(e)ine impairs endocardial endothelial function. Can J Physiol Pharmacol 1999, 77:950-957. 10.1139/cjpp-77-12-950, 10606441.
53. Mishra PK, Tyagi N, Kundu S, Tyagi SC. MicroRNAs are involved in homocysteine-induced cardiac remodeling. Cell Biochem Biophys 2009, 55:153-162. 10.1007/s12013-009-9063-6, 2863043, 19669742.
54. Garin I, Edghill EL, Akerman I, Rubio-Cabezas O, Rica I, Locke JM, et al. Recessive mutations in the INS gene result in neonatal diabetes through reduced insulin biosynthesis. Proc Natl Acad Sci USA 2010, 107:3105-3110. 10.1073/pnas.0910533107, 2840338, 20133622.
55. Hong EG, Jung DY, Ko HJ, Zhang Z, Ma Z, Jun JY, et al. Nonobese, insulin-deficient Ins2Akita mice develop type 2 diabetes phenotypes including insulin resistance and cardiac remodeling. Am J Physiol Endocrinol Metab 2007, 293:E1687-E1696. 10.1152/ajpendo.00256.2007, 17911348.
56. Adamcova M, Potacova A, Popelova O, Sterba M, Mazurova Y, Aupperle H, et al. Cardiac remodeling and MMPs on the model of chronic daunorubicin-induced cardiomyopathy in rabbits. Physiol Res 2010,
57. Awad AE, Kandalam V, Chakrabarti S, Wang X, Penninger JM, Davidge ST, et al. Tumor necrosis factor induces matrix metalloproteinases in cardiomyocytes and cardiofibroblasts differentially via superoxide production in a PI3Kgamma-dependent manner. Am J Physiol Cell Physiol 2010, 298:C679-C692. 10.1152/ajpcell.00351.2009, 20007453.
58. Mishra PK, Tyagi N, Sen U, Givvimani S, Tyagi SC. H2 S ameliorates oxidative and proteolytic stresses and protects the heart against adverse remodeling in chronic heart failure. Am J Physiol Heart Circ Physiol 2010, 298:H451-H456. 10.1152/ajpheart.00682.2009, 19933416.
59. Okada M, Yamawaki H, Hara Y. Angiotensin II enhances interleukin-1 beta-induced MMP-9 secretion in adult rat cardiac fibroblasts. J Vet Med Sci 2010, 72:735-739. 10.1292/jvms.09-0582, 20145375.
60. Maheshwari A, Singh AK, Sinha DK, Tripathi K, Prakash J. Spectrum of renal disease in malaria. J Indian Med Assoc 2004, 102:143. 146, 148.
61. Gonzalez A, Lopez B, Querejeta R, Zubillaga E, Echeverria T, Diez J. Filling pressures and collagen metabolism in hypertensive patients with heart failure and normal ejection fraction. Hypertension 2010, 55:1418-1424. 10.1161/HYPERTENSIONAHA.109.149112, 20404218.
62. Gramley F, Lorenzen J, Knackstedt C, Rana OR, Saygili E, Frechen D, et al. Age-related atrial fibrosis. Age (Dordr) 2009, 31:27-38. 10.1007/s11357-008-9077-9, 2645993, 19234766.
63. Johnson JL, Sala-Newby GB, Ismail Y, Aguilera CM, Newby AC. Low tissue inhibitor of metalloproteinases 3 and high matrix metalloproteinase 14 levels defines a subpopulation of highly invasive foam-cell macrophages. Arterioscler Thromb Vasc Biol 2008, 28:1647-1653. 10.1161/ATVBAHA.108.170548, 2851011, 18566294.
64. Boaz M, Smetana S, Weinstein T, Matas Z, Gafter U, Iaina A, et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 2000, 356:1213-1218. 10.1016/S0140-6736(00)02783-5, 11072938.
65. Bell D, Zhao Y, McCoy FP, Devine AB, McDermott BJ. Differential effects of an anti-oxidant intervention on cardiomyocyte expression of adrenomedullin and intermedin and their receptor components in chronic nitric oxide deficiency. Cell Physiol Biochem 2007, 20:269-282. 10.1159/000107513, 17762156.
66. Hahn SM, Mitchell JB, Shacter E. Tempol inhibits neutrophil and hydrogen peroxide-mediated DNA damage. Free Radic Biol Med 1997, 23:879-884. 10.1016/S0891-5849(97)00079-8, 9378367.
67. Rippe C, Lesniewski L, Connell M, LaRocca T, Donato A, Seals D. Short-term calorie restriction reverses vascular endothelial dysfunction in old mice by increasing nitric oxide and reducing oxidative stress. Aging Cell 2010, 9:304-312. 10.1111/j.1474-9726.2010.00557.x, 20121721.
68. Zhang Y, Jang R, Mori TA, Croft KD, Schyvens CG, McKenzie KU, et al. The anti-oxidant Tempol reverses and partially prevents adrenocorticotrophic hormone-induced hypertension in the rat. J Hypertens 2003, 21:1513-1518. 10.1097/00004872-200308000-00015, 12872045.